Welcome to MIRCERA®
Description: Roche ontwikkelt innovatieve medicijnen en diagnostische oplossingen voor miljoenen patiënten wereldwijd
kidney (243) ckd (76) chronic kidney disease (56) anemia (35) anaemia (7) mircera (1) methoxy polyethylene glycol-epoetin beta (1) symptomatic anaemia (1) symptomatic anemia (1)
What is MIRCERA ® ?
MIRCERA ® is a Continuous Erythropoetin Receptor Activator (C.E.R.A.) indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients.
Due to its different mode of action, MIRCERA ® closely mimics the homeostatic maintenance of erythrocyte production under normal physiological conditions 1 . This allows correction of anaemia and stable control of Haemoglobin (Hb) levels at extended, once monthly administration intervals.
Welcome to MIRCERA®